Bill takes on drug counterfeiters
This article was originally published in The Tan Sheet
Executive Summary
Rep. Mike Rogers, R-Mich., introduces legislation March 11 to beef up penalties to deter counterfeiting of prescription and nonprescription drugs. Under the Counterfeit Drug Prevention Act of 2009, H.R. 1450, counterfeit manufacturers and complicit wholesalers would face up to 20 years in prison or, in the event a fake product results in a consumer's death, a life sentence. Rogers says sales of counterfeit drugs by 2010 are expected to reach $75 billion, more than 10 percent of global pharmaceutical sales. Hi-Tech Pharmaceuticals' CEO was sentenced to 50 months in prison for counterfeit drug charges (1"The Tan Sheet" Feb. 9, 2009, In Brief)
You may also be interested in...
Hi-Tech CEO sentenced for fake drugs
Jared R. Wheat is ordered to serve 50 months in federal prison and must forfeit $3 million gained through the production and marketing of counterfeit drugs - including Xanax, Vioxx and Viagra - with other executives from Hi-Tech Pharmaceuticals. Company founder and CEO Wheat, along with his co-conspirators, established a drug manufacturing facility in rural Belize that "complied with none of the sanitary, hygienic or quality-control regulations issued by the FDA," and subsequently sold unauthorized drugs online without a prescription, the Department of Justice says in a Feb. 3 release. Judge Jack T. Camp of the U.S. District Court for the Northern District of Georgia also places the Norcross, Ga.-based supplement firm on five years' probation. A separate case in which Hi-Tech was charged with making false and misleading claims about its supplement products did not play into the criminal prosecution (1"The Tan Sheet" Aug. 25, 2008, p. 7)
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.